Tag
For this special episode of Executive Platforms’ bluEPrint Podcast series we had some of the top speakers from the 2023 edition of the long-running North American HR Executive Summit series sit down and speak to the challenges and opportunities submitted by attendees of the event as they filled out their delegate profiles, weighted by popularity.
Continue reading
As Chief People & Organization (P&O) Officer of Novartis, Rob Kowalski leads the company’s strategy to unleash the power of its people and ensure it has the diverse talent, skills and organizational capabilities to deliver on its long-term priorities and purpose as a focused medicines company.
Rob is passionate about fostering an Inspired, Curious and Unbossed culture that drives innovation and performance, and ultimately impacts how Novartis reimagines medicine for patients. Since taking his current position in 2021, he has played an instrumental role in implementing a new structure and operating model designed to support the company’s next phase of innovation and growth.
Continue reading
Rob Zamboldi is the Site Head and General Manager of Novartis’ flagship cell processing operation in Morris Plains, NJ providing worldwide supply of novel CAR-T therapies. Rob was instrumental in the ramp up of the first to market CAR-T, Kymriah ® of which more than 7,000 treatments have been supplied from his facility.
Continue reading
As President, Operations, Steffen Lang leads a team of 35,000 associates dedicated to manufacturing and supplying high-quality medicines to patients, and providing operational support to the entire Novartis enterprise. Novartis Operations incorporates the company’s manufacturing, quality, and supply organization, as well as information technology, data and digital, procurement, environmental sustainability, facility services, and other global services.
Prior to taking on this role, Steffen was Global Head of Novartis Technical Operations (NTO). Under his leadership, NTO underwent a transformation to become one of the leading manufacturing and supply organizations in the industry, providing agile, efficient support to the business, and reliably delivering life-changing medicines to patients around the world. During this time, the unit adapted its manufacturing capacity and capabilities to the changing needs of the Novartis strategy and product portfolio, maximizing the potential of its assets and expertise. As well as delivering technological innovation to enable the production of advanced therapeutic platforms, the unit collaborated with industry partners to support global demand for COVID-19 vaccines and therapies.
Continue reading
Beyond the buzzwords: Sharing lessons learned from a multi-year, global, culture transformation journey Discussing the role of upper management in shifting the culture of an organization Exploring the role of HR and evolution of HR practices to impact organizational culture — Fenella Chisholm SVP, Global People & Organization Novartis Fenella Chisholm is SVP and Global Head People & Organization for the Novartis Institutes for BioMedical Research (NIBR). In this role, Fenella partners with leadership across the 6000 strong global early discovery science unit to operationalize the Novartis People strategy in service of the vision to Reimagine Medicine and deliver better…
Continue reading
Investing capital in capacity expansion when a drug is early in development is challenging. There are new manufacturing models that reduce risk and add value to your decisions through a concept called optionality Balancing options and critically evaluated risk against probability of success in to-build decisions Introducing a new biomanufacturing solution that leverages manufacturing ecosystems to reduce the need to build infrastructure Effectively transfer non-value added work from the manufacturing site to service providers with this new manufacturing model — Daniel Palmacci has nearly 20 years of leadership experience in Biologics in the area of manufacturing, technical development, supply chain,…
Continue reading
